AML is routinely diagnosed based on cytology of peripheral blood or bone marrow, most importantly the detection of > 10–20% blasts, in combination with cytogenetics and molecular genetic analyses to detect specific AML-related mutations such as NPM1, CEBPA, FLT3-ITD/-TKD or IDH1/2. Here, IDH1 is linked to acute myeloid leukemia.